Market research
CDTX Cidara Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 7B
- P/E ratio
- Not available
- Analyst target
- 221.5
- Dividend yield
- Not available
- Beta
- 1.53
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US1717572069
- Market cap
- 7B
- P/E ratio
- Not available
- Analyst target
- 221.5
- Dividend yield
- Not available
- Beta
- 1.53
About
About Cidara Therapeutics Inc
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CDTX discussion.
5 years, 4 months ago
Cidara Therapeutics, Inc is currently in a long term downtrend where the price is trading 18.7% below its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 9.3.
Cidara Therapeutics, Inc's total revenue rose by 105.5% to $4M since the same quarter in the previous year.
Its net income has dropped by 54.3% to $-22M since the same quarter in the previous year.
Finally, its free cash flow grew by 26.9% to $-11M since the same quarter in the previous year.
Based on the above factors, Cidara Therapeutics, Inc gets an overall score of 3/5.